| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
|
N Engl J Med
|
2007
|
12.17
|
|
2
|
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
|
Lancet
|
2007
|
6.01
|
|
3
|
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
|
J Infect Dis
|
2009
|
5.09
|
|
4
|
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
|
J Infect Dis
|
2009
|
3.55
|
|
5
|
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
|
BMJ
|
2010
|
3.41
|
|
6
|
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
|
Lancet
|
2007
|
3.10
|
|
7
|
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
|
J Infect Dis
|
2009
|
2.92
|
|
8
|
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
|
BMJ
|
2012
|
2.77
|
|
9
|
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
|
J Infect Dis
|
2007
|
2.17
|
|
10
|
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.
|
Obstet Gynecol
|
2009
|
2.13
|
|
11
|
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia.
|
Sex Transm Infect
|
2011
|
1.78
|
|
12
|
Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease.
|
J Infect Dis
|
2012
|
1.39
|
|
13
|
Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
|
J Infect Dis
|
2007
|
1.20
|
|
14
|
Human papillomavirus infections and vulvar disease development.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.15
|
|
15
|
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
|
Int J Cancer
|
2011
|
1.12
|
|
16
|
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.
|
Vaccine
|
2007
|
1.03
|
|
17
|
Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
|
Vaccine
|
2014
|
1.02
|
|
18
|
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women.
|
Int J Cancer
|
2008
|
1.00
|
|
19
|
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.
|
Int J Cancer
|
2011
|
0.95
|
|
20
|
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
|
Am J Obstet Gynecol
|
2008
|
0.95
|
|
21
|
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women.
|
J Adolesc Health
|
2012
|
0.91
|
|
22
|
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
|
Value Health
|
2008
|
0.84
|
|
23
|
Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV.
|
J Immunol Res
|
2015
|
0.84
|
|
24
|
Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.
|
Int Rev Immunol
|
2012
|
0.77
|
|
25
|
Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.
|
Wien Klin Wochenschr
|
2008
|
0.75
|